Anbio Biotechnology (NNNN)

Market Cap	730.35M +97.9%
Revenue (ttm)	8.65M +5.6%
Net Income	6.40M +169.9%
EPS	0.15 +161.3%
Shares Out	43.89M
PE Ratio	113.49
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,267
Open	16.80
Previous Close	15.86
Day's Range	16.00 - 16.92
52-Week Range	9.20 - 55.65
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 7, 2026

About NNNN

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Feb 19, 2025
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: NNNN
• Website: https://www.anbiobiotechnology.com

Financial Performance

In 2025, Anbio Biotechnology's revenue was $8.65 million, an increase of 5.64% compared to the previous year's $8.19 million. Earnings were $6.40 million, an increase of 169.86%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jun 19, 2026

Data Sources Report a data error